Loading
A year of adjuvant nivolumab after surgery for high-risk melanoma reduced recurrences more than the previous standard, high-dose ipilimumab, with a quarter of the severe toxicity, making PD-1 blockade the adjuvant standard.
Phase 3 trial of 906 patients with resected stage IIIB, IIIC or IV melanoma randomised to nivolumab or ipilimumab 10 mg/kg for one year.
Twelve-month recurrence-free survival was 70.5 versus 60.8 percent (hazard ratio 0.65), with grade 3 to 4 treatment-related adverse events in 14.4 versus 45.9 percent; four-year recurrence-free survival was 51.7 versus 41.2 percent, with no overall survival difference.
Adjuvant nivolumab (or pembrolizumab) is standard for resected stage III and IV melanoma; ipilimumab is no longer used in the adjuvant setting.
Shares CheckMate 238, Stage III melanoma (after surgery), Ipilimumab, Nivolumab.
Shares Ipilimumab, Nivolumab, New England Journal of Medicine.
Shares Stage III melanoma (after surgery), New England Journal of Medicine.
Shares Stage III melanoma (after surgery), New England Journal of Medicine.
Shares CheckMate 238, Ipilimumab, Nivolumab.
Shares Ipilimumab, Nivolumab.
Shares Stage III melanoma (after surgery), Ipilimumab, Nivolumab.